TG Therapeutics announces licensing agreement with Ildong
TG Therapeutics and Ildong Pharmaceutical Co have inked a licensing agreement for the development and commercialisation of ublituximab
US biopharmaceutical company TG Therapeutics has entered into an exclusive licensing agreement with Ildong Pharmaceutical Co, a Korean company focused on pharmaceutical and over-the-counter products.
TG Therapeutics will receive an upfront payment of $2 million, along with milestone and royalty payments, in exchange for exclusive rights to develop and commercialise novel anti-CD20 antibody ublituximab (TGTX-1101) in South Korea and south-east Asia.
Ublituximab is currently being developed by TG Therapeutics for the treatment of haematologic malignancies and B-cell related disorders.
At present, it is being evaluated in a phase-I/II trial involving patients with relapsed or refractory non-Hodgkin's lymphoma.
Michael Weiss, chairman and interim chief executive officer of TG Therapeutics, described ublituximab as a "promising treatment".
He said: "We are excited to work with the experienced team at Ildong to expand the scope of development for ublituximab."
Jung-Chi Lee, Ildong's chairman & chief executive officer, claimed that ublituximab would strengthen the company's presence in the fields of oncology and autoimmune disease.
He added that the company "look forward to working with TG Therapeutics in developing ublituximab in South Korea and south-east Asia".
Related News
-
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.
-
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF).
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development.